

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Recombinant Anti-GCLC antibody [EP13475]

RRID:AB_2889925

Type: Antibody

Proper Citation

Abcam Cat# ab190685, RRID:AB_2889925

Antibody Information

URL: http://antibodyregistry.org/AB_2889925

Proper Citation: Abcam Cat# ab190685, RRID:AB_2889925

Target Antigen: GCLC

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IP

Antibody Name: Recombinant Anti-GCLC antibody [EP13475]

Description: This recombinant monoclonal targets GCLC

Target Organism: rat, mouse, human

Clone ID: EP13475

Antibody ID: AB_2889925

Vendor: Abcam

Catalog Number: ab190685

Record Creation Time: 20231110T031648+0000

Record Last Update: 20260830T020156+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-GCLC antibody [EP13475].

No alerts have been found for Recombinant Anti-GCLC antibody [EP13475].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang Y, et al. (2026) Nociceptive neurons protect cancer cells against oxidative stress. Cell reports, 45(3), 117086.

Wu G, et al. (2024) Design, synthesis and biological evaluation of N-salicyloyl tryptamine derivatives as multifunctional neuroprotectants for the treatment of ischemic stroke. European journal of medicinal chemistry, 278, 116795.

He J, et al. (2023) Reprogramming of iron metabolism confers ferroptosis resistance in ECM-detached cells. iScience, 26(6), 106827.

Kim Y, et al. (2023) Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer. Cell reports. Medicine, 4(10), 101224.

LaPak KM, et al. (2023) Proximity proteomic analysis of the NRF family reveals the Parkinson's disease protein ZNF746/PARIS as a co-complexed repressor of NRF2. Science signaling, 16(815), eadi9018.

Laoukili J, et al. (2022) BRAFV600E in colorectal cancer reduces sensitivity to oxidative stress and promotes site-specific metastasis by stimulating glutathione synthesis. Cell reports, 41(9), 111728.